Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Avalo Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 33 | 34 | +1 |
| Shares | 7.53M | 8.26M | +724.5K (+9.6%) |
| Value | $56.0M | $66.1M | +$10.2M (+18.2%) |
New holders (5)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 900,000 | $7.21M | 0.60% |
| Perceptive Advisors LLC | 520,000 | $4.17M | 0.15% |
| Adviser Investments LLC | 312,779 | $2.51M | 0.03% |
| ADAR1 Capital Management, LLC | 10,000 | $80.1K | 0.02% |
| Avion Wealth | 5 | $0 | 0.00% |
Sold out (4)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Boothbay Fund Management, LLC | 163,992 | $1.22M |
| Bank of Montreal | 60,000 | $445.8K |
| Marshall Wace, LLP | 15,323 | $113.8K |
| Tower Research Capital LLC (TRC) | 4,130 | $30.7K |